Over 115 companies, across the world, claim to offer a variety of product development/RootsAnalysis
Despite mammalian cell cultures being the preferredmanufacturing approach for biologics, recent advances in microbial fermentationhave enabled the development of versatile biomanufacturing systems, which areboth robust and cost friendly. Presently, a number of service providercompanies claim to offer end-to-end solutions, ranging from product developmentto commercial production, for microbial biologics. Given the obvious advantagesof outsourcing, drug developers are likely to continue relying on contractservice providers for various aspects of their respective microbial biologicdevelopment programs.
To order this 320+ page report, which features 150+ figuresand 150+ tables, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
The USD 9.3 billion (by 2030) financial opportunity withinthe microbial biomanufacturing market has been analyzed across the followingsegments:
§ Type of Product
§ API
§ FDF
§ Type of Biologic
§ Proteins
§ Enzymes
§ Growth Hormones
§ Antibody based Drugs
§ Others (plasmidDNA, probiotics, microbiome-based biologics)
§ Type of MicrobialExpression System
§ Bacteria
§ Yeast
§ Others (Algae andfungi)
§ Scale of Operation
§ Commercial
§ Preclinical /Clinical
§ Type of End User
§ Small Companies
§ Mid-sized Companies
§ Large / Very LargeCompanies
§ Key GeographicalRegions
§ North America
§ Europe
§ Asia Pacific
§ Middle East and NorthAfrica
§ Latin America
The MicrobialContract Biomanufacturing Market,2020-2030 report features the following companies, which weidentified to be key players in this domain:
§ AGC Biologics
§ Aldevron
§ BioVectra
§ EirGenix
§ Etinpro
§ Eurogentec
§ NorthwayBiotechpharma
§ Ology Bioservices
§ Porton Biopharma
§ Stelis Biopharma
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Company Competitiveness Analysis
6. Company Profiles
7. Recent Partnerships
8. Recent Expansions
9. Microbialfermentation technology platforms
10. Assessment of Relative Competition and Growth
11. Make versus Buy Decision Making Framework
12. Big PharmaInitiatives in Microbial Biomanufacturing
13. Case study: comparison of small molecule and large
14. Market Sizing and Opportunity Analysis
15. Impact of covid-19 pandemic on microbial contractbiomanufacturing market
16. Swot Analysis
17. Conclusion Appendix 3: List of Companies andOrganizations
18. Interview Transcripts
19. Appendix 1: Tabulated Data
20. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
